Awards & Advancement

Flex Pharma names William McVicar President and CEO

Tuesday, August 1, 2017

Flex Pharma, a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced that the Board of Directors has appointed William McVicar, Ph.D., as President and Chief Executive Officer of Flex Pharma.

[Read More]

Biogen appoints Anabella Villalobos SVP, Biotherapeutic & Medicinal Sciences

Tuesday, August 1, 2017

Biogen announced the appointment of Anabella Villalobos, Ph.D., as senior vice president, Biotherapeutic & Medicinal Sciences (BTMS). Dr. Villalobos will lead Biogen’s BTMS organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, M.D., Ph.D., executive vice president, Head of Research and Development.

[Read More]

Colleen Goggins joins QuintilesIMS Board of Directors

Thursday, July 27, 2017

QuintilesIMS, a provider of information, technology solutions and contract research services to the life sciences industry, announced the appointment of Colleen Goggins to its board of directors, effective today. A senior executive at Johnson & Johnson for more than three decades, Goggins retired in 2011 after serving ten years on J&J’s Executive Committee and as the Worldwide Chairman of its Consumer Group. Under her leadership, the J&J global personal and healthcare portfolio, comprising many of the most recognized consumer brands and medicines in the world, grew to more than $16 billion in annual revenue.

[Read More]

The All of Us Research Program announces first community partner awards

Tuesday, July 25, 2017

The National Institutes of Health announced its first four community partner awards to begin building a national network of trusted leaders to motivate diverse communities to join the All of Us Research Program, part of the Precision Medicine Initiative. This initial group of awardees will receive a combined $1.7 million this fiscal year, with future support planned pending the availability of funds. These awardees will raise awareness about the program among seniors, Hispanics and Latinos, African Americans and the LGBTQ community, to complement other outreach efforts of the program. NIH anticipates making additional funding awards for community partners in the future, drawing on the lessons learned from this initial set of awardees.

[Read More]

Vaxil BioTherapeutics appoints Dr. Terry Plasse chief medical officer

Tuesday, July 25, 2017

Vaxil Bio, an Israeli-Canadian biotech developing innovative immunotherapy treatments for cancer, announced the appointment of Dr. Terry Plasse as its chief medical officer, responsible for the company’s clinical program surrounding its drug candidate, ImMucin. Dr. Plasse brings 30 years of clinical development experience, including advancing products from IND through to commercially marketed treatments for several big-pharma companies.

[Read More]

Median Technologies awarded Futur40 Prize by Forbes France

Wednesday, July 19, 2017

Median Technologies, the Imaging Phenomics Company, announced that on it was awarded the Futur40 Prize by Forbes France, in association with PME finance – Europe Entrepreneurs, the French Finance Association Paris Europlace and the Federation of Individual Investors and the Finance Clubs (F2iC – Fédération des Investisseurs Individuels et des Clubs d’investissement).

[Read More]